Skip to main content

Table 2 Univariate analysis of the effects of clinicopathological characteristics on survival in 7103 GCA patients treated with different surgical approaches

From: Transthoracic, thoracoabdominal, and transabdominal surgical approaches for gastric cardia adenocarcinomas: a survival evaluation based on a cohort of 7103 patients

Characteristics

Median survival (95% CI)

Pa

Pb

Transthoracic

Thoracoabdominal

Transabdominal

Sex

 Male

5.66 (5.37–5.94)

4.66 (4.27–5.05)

3.84 (3.15–4.53)

 < 0.001*

 < 0.001

 Female

5.69 (5.08–6.29)

5.73 (3.53–7.94)

4.79 (3.60–5.98)

0.32

Age (years)

  < 40

5.02 (1.93–8.12)

3.29 (0.34–6.24)

Not reached

0.34

 < 0.001

 40–49

7.27 (5.23–9.31)

7.27 (5.33–9.22)

3.55 (1.98–5.12)

0.10

 50–59

7.04 (6.34–7.74)

4.95 (4.19–5.71)

6.268 (4.22–8.32)

0.02

 60–69

5.68 (5.31–6.04)

4.73 (4.05–5.40)

4.088 (3.33–4.84)

0.002†

 70–79

4.00 (3.65–4.36)

3.50 (2.19–4.82)

2.70 (1.72–3.68)

0.005‡

  ≥ 80

3.51 (2.84–4.18)

3.55 (1.49–5.61)

1.22 (0.56–1.88)

0.16

Tumor stage

 0/I

13.09 (8.90–17.27)

9.39 (4.49–14.29)

Not reached

0.60

 < 0.001

 II

7.70 (7.08–8.33)

7.02 (5.26–8.78)

6.95 (2.61–11.28)

0.41

 III

4.23 (4.02–4.45)

3.79 (3.31–4.27)

3.16 (2.58–3.73)

 < 0.001

 IV

4.99 (3.60–6.38)

3.09 (1.51–4.68)

3.01 (1.53–4.50)

0.03

N stage

 N0

8.99 (8.23–9.75)

8.51 (6.38–10.64)

6.95 (2.67–11.22)

0.31

 < 0.001

 N1

4.46 (4.26–4.67)

3.93 (3.55–4.31)

3.16 (2.66–3.67)

 < 0.001

  1. *Transthoracic vs. thoracoabdominal, P < 0.001; transthoracic vs. transabdominal, P < 0.001; thoracoabdominal vs. transabdominal, P = 0.08
  2. †Transthoracic vs. thoracoabdominal, P = 0.12; transthoracic vs. transabdominal, P = 0.001; thoracoabdominal vs. transabdominal, P = 0.08
  3. ‡Transthoracic vs. thoracoabdominal, P = 0.20; transthoracic vs. transabdominal, P = 0.001; thoracoabdominal vs. transabdominal, P = 0.14